中国药理学通报
中國藥理學通報
중국약이학통보
CHINESE PHARMACOLOGICAL BULLETIN
2010年
4期
547-551
,共5页
周才秀%王忠%荆志伟%张占军
週纔秀%王忠%荊誌偉%張佔軍
주재수%왕충%형지위%장점군
清开灵%脑缺血%芯片%基因%GeneGo%信号通路
清開靈%腦缺血%芯片%基因%GeneGo%信號通路
청개령%뇌결혈%심편%기인%GeneGo%신호통로
Qingkailing%cerebral ischemia%biochips%genes%GeneGo%signaling pathways]
目的 比较清开灵有效组分BA(黄芩苷)、JA(栀子苷)、CA(胆酸)与CM(珍珠母)在治疗脑缺血过程中药理通路变化机制.方法 将脑缺血模型小鼠随机分为BA、JA、CA、CM和M(模型组),每组15只,脑缺血后2 h予以相应药物治疗,24 h后断头取脑,抽提小鼠脑海马组织的总RNA,利用与脑缺血相关的374个基因的cDNA芯片检测基因表达谱变化.将所有数据标准化处理后,以Arraytrack软件为平台,选取BA与M,JA与M,CA与M和CM与M两组间t检验得出的差异基因(P<0.05,Fold change>1.5),将差异表达基因按照Genebank ID上传到GeneGo数据库,选取P<0.05的信号通路,选取各组分P值最小的前2位药理通路分析不同组分的药效机制.结果 BA、JA、CA、CM与M组比较后差异基因数量分别为46、50、54和30条,根据这4个组分差异基因相似度最大的前2位信号通路可看出JA、CA、CM都参与凋亡与存活_TNFR1信号通路的调控,另外BA表现为对G蛋白信号和A2A受体信号的调控作用,CA表现为调节NMDA依赖性的LTP的调节.结论 清开灵组分发挥药效作用具有多样性特点,BA主要表现为抗凋亡,JA主要表现为抑制细胞凋亡和促进缺血后脑保护等方面,CA侧重于抑制钙离子内流,抗神经元变异方面,但CM效果不甚理想.
目的 比較清開靈有效組分BA(黃芩苷)、JA(梔子苷)、CA(膽痠)與CM(珍珠母)在治療腦缺血過程中藥理通路變化機製.方法 將腦缺血模型小鼠隨機分為BA、JA、CA、CM和M(模型組),每組15隻,腦缺血後2 h予以相應藥物治療,24 h後斷頭取腦,抽提小鼠腦海馬組織的總RNA,利用與腦缺血相關的374箇基因的cDNA芯片檢測基因錶達譜變化.將所有數據標準化處理後,以Arraytrack軟件為平檯,選取BA與M,JA與M,CA與M和CM與M兩組間t檢驗得齣的差異基因(P<0.05,Fold change>1.5),將差異錶達基因按照Genebank ID上傳到GeneGo數據庫,選取P<0.05的信號通路,選取各組分P值最小的前2位藥理通路分析不同組分的藥效機製.結果 BA、JA、CA、CM與M組比較後差異基因數量分彆為46、50、54和30條,根據這4箇組分差異基因相似度最大的前2位信號通路可看齣JA、CA、CM都參與凋亡與存活_TNFR1信號通路的調控,另外BA錶現為對G蛋白信號和A2A受體信號的調控作用,CA錶現為調節NMDA依賴性的LTP的調節.結論 清開靈組分髮揮藥效作用具有多樣性特點,BA主要錶現為抗凋亡,JA主要錶現為抑製細胞凋亡和促進缺血後腦保護等方麵,CA側重于抑製鈣離子內流,抗神經元變異方麵,但CM效果不甚理想.
목적 비교청개령유효조분BA(황금감)、JA(치자감)、CA(담산)여CM(진주모)재치료뇌결혈과정중약리통로변화궤제.방법 장뇌결혈모형소서수궤분위BA、JA、CA、CM화M(모형조),매조15지,뇌결혈후2 h여이상응약물치료,24 h후단두취뇌,추제소서뇌해마조직적총RNA,이용여뇌결혈상관적374개기인적cDNA심편검측기인표체보변화.장소유수거표준화처리후,이Arraytrack연건위평태,선취BA여M,JA여M,CA여M화CM여M량조간t검험득출적차이기인(P<0.05,Fold change>1.5),장차이표체기인안조Genebank ID상전도GeneGo수거고,선취P<0.05적신호통로,선취각조분P치최소적전2위약리통로분석불동조분적약효궤제.결과 BA、JA、CA、CM여M조비교후차이기인수량분별위46、50、54화30조,근거저4개조분차이기인상사도최대적전2위신호통로가간출JA、CA、CM도삼여조망여존활_TNFR1신호통로적조공,령외BA표현위대G단백신호화A2A수체신호적조공작용,CA표현위조절NMDA의뢰성적LTP적조절.결론 청개령조분발휘약효작용구유다양성특점,BA주요표현위항조망,JA주요표현위억제세포조망화촉진결혈후뇌보호등방면,CA측중우억제개리자내류,항신경원변이방면,단CM효과불심이상.
AimPurpose-The aim of this study is utilizing the highthrough genechip data to Compare the difference of the pharmacological pathways among the Qingkailing effective components Baicalin(BA),Jasminoidin(JA),cholic acid(CA) and Concha margaritiferausta(CM)in the treatment process of cerebral ischemia.Methods The focal cerebral ischemia-reperfusion model mice were randomly divided into groups of Baicalin(BA),Jasminoidin(JA),cholic acid(CA),Concha margaritiferausta(CM)and model group(M),15 mice for each group,24 hours later total RNA were abstracted from the hippocampus,we selected 374 gene expression profile related to cerebral ischemia,made cDNA chip marked by Cy3/Cy5,detect the variation of different components,Then apply Arraytrack software to select differentiate expressed genes between BA and M,JA and M,CA and M,CM and M by T-tests,select genes with P<0.05,Fold change>1.5,according GeneGO software to find the top two pathways of each components.Results the number of differentiate expressed genes between BA,JA,CA,CM and M is separately 46,50,54 and 30,according to the top two pathways of GeneGo display JA,CA,CM all participate Apoptosis and survival_TNFR1 signaling pathway,besides BA participate in regulating G-protein signaling and Development_A2A receptor signaling while CA in Neurophysiological process_NMDA-dependent postsynaptic long-term potentiation in CA1 hippocampal.Conclusion Qingkailing effective components take diversity Pharmacological characteristics,BA mainly for anti-apoptosis,JA mainly for inhibit apoptosis and promote ischemic brain protection,etc,CA focused on inhibiting calcium influx,and anti-neuron variability.But CM has no good results on this.
